Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Galunisertib - Eli Lilly and Company

Drug Profile

Galunisertib - Eli Lilly and Company

Alternative Names: LY-2157299

Latest Information Update: 19 Aug 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer AstraZeneca; Eli Lilly and Company; National Cancer Institute (USA); University of Oklahoma; Vanderbilt-Ingram Cancer Center; Weill Cornell Medical College
  • Class Antineoplastics; Pyrazoles; Pyridines; Pyrroles; Quinolines; Small molecules
  • Mechanism of Action Phosphotransferase inhibitors; Transforming growth factor beta1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Cancer; Colorectal cancer; Glioblastoma; Glioma; Liver cancer; Myelodysplastic syndromes; Non-small cell lung cancer; Pancreatic cancer; Rectal cancer; Sarcoma; Solid tumours

Most Recent Events

  • 29 May 2020 Efficacy and adverse events data from a phase I trial in Liver cancer presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO-2020)
  • 25 Dec 2019 Eli Lilly completes a phase I trial in Liver cancer (Combination therapy, Inoperable/Unresectable) in Japan (PO) (NCT02240433)
  • 30 Jul 2019 Discontinued - Phase-I for Breast cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (PO) (Eli Lilly Pipeline - July 2019)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top